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Abstract
Dose nding studies often compare several doses of a new compound with a mar-
keted standard treatment as an active control. In the past, however, research has
focused mostly on experimental designs for placebo-controlled dose nding studies. To
the best of our knowledge, optimal designs for dose nding studies with an active con-
trol have not been considered so far. As the statistical analysis for an active controlled
dose nding study can be formulated in terms of a mixture of two regression models,
the related design problem is dierent to what has been investigated before in the
literature. We present a rigorous approach to the problem of determining optimal de-
signs for estimating the smallest dose achieving the same treatment eect as the active
control. We determine explicitly the locally optimal designs for a broad class of mod-
els employed in such studies. We also discuss robust design strategies and determine
related Bayesian and standardized minimax optimal designs. We illustrate the results
by investigating alternative designs for a clinical trial which has recently appeared in
a consulting project of one of the authors.
Keywords and Phrases. minimax design, Bayesian optimal designs, dose response, dose es-
timation, active control
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1 Introduction
One of the critical steps in developing a medicinal drug is a proper understanding and char-
acterization of its dose response relationship. Failing to characterize well the dose response
relationship may have severe consequences once the drug is available to patients: selecting
too high doses may lead to unacceptable safety problems, while selecting too low doses may
lead to insucient ecacy. Further applications, where dose response modeling is of partic-
ular importance, include the investigation of a new herbicide or fertilizer, a molecular entity,
an environmental toxin, or an industrial chemical.
Much literature is available on dose response studies including a placebo group (see Ruberg
(1995), Ting (2006), Bretz et al. (2008) among many others). However, in some drug devel-
opment programs the dose dependent ecacy relative to a standard treatment is of major
interest, especially in preparation for an active-controlled conrmatory non-inferiority trial.
In addition to regulatory requirements related to drug approval, health technology assess-
ments for national reimbursement decisions may be improved by dose nding studies that
evaluate the incremental dose eect as compared to the standard treatment. Furthermore,
in many situations the use of placebo could be considered unethical or unfeasible, even in
a Phase II dose nding study. If no placebo is used the extrapolation of the dose response
from the lowest dose to the zero dose (i.e. placebo) becomes problematic and the use of an
active control could facilitate the assessment of the overall ecacy level of the dose response
curve.
The considerable interest by regulatory agencies in active-controlled studies becomes evident
from several related guidelines. For example, the tripartite ICH E4 guideline on dose nding
encourages the inclusion of an active comparator in a dose nding study to improve assay
sensitivity of the trial as well as to generate better data on comparative eectiveness and
safety (ICH, 1994). In addition, several international disease-specic regulatory guidelines
recommend the use of an active comparator in pivotal Phase III studies (EMEA, 2006, 2011).
In a more general context, the EMEA guideline on the choice of a non-inferiority margin
states that a placebo-controlled trial is usually not sucient and that the comparison between
test and reference will often be of importance in its own right (EMEA, 2005). It thus becomes
evident that due to the regulatory requirements on active-controlled Phase III trials, dose
nding studies with an active control contribute signicantly to the proper choice of a dose to
be used in Phase III and lead to a better risk-benet prole in comparison with a marketed
drug.
The research in the present paper is motivated by an active-controlled dose-nding Phase
II study to determine the optimal dose of the new compound for the management of acute
are in gout adult patients who are refractory or contraindicated to standard therapies. The
primary objective is to determine the target dose of the new compound, which is the dose
that leads to the same ecacy as the active control. It will be identied by assessing the dose
response relationship of various doses of the new compound with regard to pain intensity
in the target joint at 72 hours (Day 4) post-dose measured on a 0   100mm Visual Analog
2
Scale (VAS). Approximately 200 patients will be included in the study. Patients who meet
the entry criteria will be randomized to receive either the active control or one dose of the
new compound. An important problem consists in specifying the dose levels for the new
compound as well as the allocation ratio of patients across all treatments arms in this study.
Once the optimal dose of the new compound is selected on the basis of this Phase II trial,
Phase III studies will be conducted to evaluate further the ecacy and safety of the new
compound in the respective patient population (either acute or chronic gout patients).
It is well known that optimal designs can substantially improve the eciency of statistical
analyzes and numerous authors have worked on the problem of constructing optimal designs
for placebo-controlled dose response studies (see Miller et al. (2007), Dragalin et al. (2007),
Dette et al. (2008), Dette et al. (2010) among others). However, to our best knowledge,
optimal design problems for active controlled dose nding studies have not been considered
in the literature so far. In this paper we propose a strategy to obtain ecient designs for such
situations. In Section 2 we introduce the statistical model that includes an active control
together with several dose levels of the compound under investigation. Locally optimal
designs for estimating the target dose for the new compound are constructed explicitly. These
designs require a-priori information about the unknown model parameters [see Cherno
(1953), Ford et al. (1992), Fang and Hedayat (2008)] and usually serve as benchmarks for
commonly used designs. In addition, locally optimal designs serve as basis for constructing
optimal designs with respect to more sophisticated optimality criteria, which are robust
against a misspecication of the unknown parameters [see Pronzato and Walter (1985) or
Chaloner and Verdinelli (1995), Dette (1997), Imhof (2001) among others]. In Section 3 we
consider standardized minimax and Bayesian optimal designs, which minimize the maximal
eciency and average eciency over a given range of the unknown parameters, respectively.
For several models, including the widely used EMAX model, it is demonstrated that the
robust designs are saturated (i.e. the number of dierent conditions coincides with the
number of parameters for the underlying model) and optimal designs with respect to these
criteria are determined explicitly. Several examples illustrating the results are presented in
Section 4, where we also study the eciency of commonly used designs for the case study
described above. Finally, some conclusions and directions for further research are presented
in Section 5, while Section 6 contains the proofs of our main results.
2 A statistical model for active-controlled dose nding
studies
We assume that patients are treated either with an active control (a standard treatment
administered at a xed dose level) or with the new drug for which the dose response re-
lationship is unknown. For a given total sample size, say n, the goal of an experimental
design is to allocate n1 and n2 = n   n1 patients to the new drug and the active control,
respectively, and to determine the dose levels under which the n1 patients are treated with
3
the new drug.
For the statistical analysis we assume that the observations are realizations of independent
random variables Y1; : : : ; Yn1 ,Z1; : : : ; Zn2 according to the model
Yi = f(di; ) + "i for 1  i  n1;
Zi = + "n1+i for 1  i  n2;
where "1; : : : ; "n are independent and normally distributed with expectation 0 and variance
2. The random variable Yi corresponds to a patient receiving the new drug at dose level
di (i = 1; : : : ; n1) and Zi corresponds to a patient receiving the active control (at a xed single
dose level). Furthermore,  is the expected eect for the active contol,  = (#0; : : : ; #p)
T 2
  Rp+1 denotes a vector of unknown parameters and f is a given function which describes
the average response dose of the new drug at a given dose.
Let  be an indicator, whether a patient receives the new drug ( = 0) or the active control
( = 1). The design space is therefore given by the set
X = (XD  f0g) [ f(C; 1)g;
where XD denotes the dose range for the new drug, C is the dose level of the active control
and the second component of an experimental condition (d; ) determines the treatment
( = 0; 1). Straightforward calculation shows that the Fisher information at (d; ) is given
by the matrix (d; )T (d; ) where the function  : X ! Rp+2 is dened by
 ((d; ); ) =
( 
gT (d; ); 0
T
if  = 0 
0T ; 1
T
if  = 1
(2.1)
and
g(d; ) =
@f(d; )
@#0
; : : : ;
@f(d; )
@#p
T
(2.2)
denotes the gradient of the regression function f(d; ) with respect to the vector . Through-
out this paper we consider approximate designs in the sense of Kiefer (1974), which are
dened as probability measures with nite support on the design space X . Therefore, an
experimental design is given by
 =

(d1; 0) : : : (dk; 0) (C; 1)
w1 : : : wk wk+1

where w1; : : : ; wk+1 are positive weights, such that
Pk+1
j=1 wj = 1. The weight wk+1 denotes
the relative proportion of total observations treated with the active control, d1; : : : ; dk the
dierent dose levels used for the new drug and wj the relative proportion of patients treated
at dose level dj (j = 1; : : : ; k). The information matrix of an approximate design is given by
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the (p+ 2) (p+ 2) matrix
M(; ) =
Z
X
((d; ); )T ((d; ); )d(d; )
=
kX
j=1
wj

g(dj; )
0
 
gT (dj; ); 0

+ wk+1

0 0
0 1

=

(1  wk+1) ~M(~; ) 0
0 wk+1

where the (p+ 1) (p+ 1) matrix ~M(~; ) is dened by
~M(~; ) =
Z
XD
g(d; )gT (d; )d~(d) (2.3)
and
~ =

d1 : : : dk
~w1 : : : ~wk

(2.4)
denotes a design (on the design space XD) for the new drug with weights
~wi =
wi
1  wk+1 ; i = 1; : : : ; k:
In the following we consider models of the form
f(d; ) = #0 + #1f2(d) (2.5)
where 2 = (#2; : : : ; #p)
T , the function f2 is assumed to be strictly increasing, see Bretz et al.
(2005). The aim is to estimate the target dose d = d(; ) = f 1(; ) = f 12 (
 #0
#1
) for a
xed value of , i.e. the smallest dose of the new compound achieving the same treatment
eect as the active control. A natural estimate of d is given by d^ = f 1(^; ^), where (^; ^)
is the maximum likelihood estimate of the parameter  = (; ). Standard calculation shows
that the variance of this estimator is approximately given by
Var(d^)  
2
n
 (; );
where the function  is dened by
 (; ) =  (; ; ) = rd(; )M (; )rdT (; ) (2.6)
=
1
1  wk+1rd
(; ) ~M (~; )rdT (; ) +

@d(; )
@
2
1
wk+1
:
Here, r denotes the gradient of the function d with respect to the parameter  = (; ),
r the gradient with respect to , and M (; ) and ~M (; ) are generalized inverses of
the information matrices M(; ) and ~M(; ), respectively. A design  is called locally
AC-optimal design (for Active Control) if rd(; ) 2 Range(M(; )) and if  minimizes
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the function  (; ) among all designs satisfying this condition. The identity in (2.6) holds,
because for a design with rd(; ) 2 Range(M(; )) the variance is independent of the
choice of the general inverse [see Pukelsheim (2006)]. Therefore we choose a generalized
inverse with the same block structure as the information matrix. Note that the optimality
criterion (2.6) is a special case of the c-optimality criterion, which corresponds to minimizing
the expression
cTM (; )c; (2.7)
for a given vector c 2 Rp+1 in the class of all design , such that c is estimable by the given
design , i.e. Range(c)  Range(M(; )).
In the next result we determine locally AC-optimal designs for a broad class of nonlinear
regression models accounting for an active control by minimizing the criterion (2.6). These
designs serve as benchmarks for commonly used designs and are the basis for the construc-
tion of optimal designs with respect to more sophisticated optimality criteria, in particular
standardized minimax and Bayesian optimal designs discussed in the following section. Since
the seminal paper of Cherno (1953) numerous authors have worked on the problem of con-
structing locally optimal designs for many regression problems [see for example Ford et al.
(1992), He et al. (1996), Fang and Hedayat (2008) or Yang (2010) among many others] but
- to the best knowledge of the authors - optimal design problems for active controlled dose
nding studies have not been considered in the literature. In the following result we show
that for all models of the form (2.5) there exist locally AC-optimal designs with two support
points independently of the dimension of the parameter vector . The proof is based on the
implicit function theorem and given in the Appendix.
Theorem 2.1 For a model of the form (2.5) the optimality criterion dened in (2.6) has
the representation
 (; ; ) =

@d(; )
@
2
1
1  wk+1 g
T (d; ) ~M (~; )g(d; ) +
1
wk+1

;
where d = d(; ) = f 12 (
 #0
#1
) and the matrix ~M(~; ) and the design ~ are dened by
(2.3) and (2.4), respectively. Moreover, for the model (2.5) with d 2 XD the design
 =

(d; 0) (C; 1)
1
2
1
2

(2.8)
is a locally AC-optimal design. In particular, the minimum value of the criterion  dened
in (2.6) is given by
min

 (; ; ) =  ( ; ; ) = 4
@d(; )
@
2
:
It is of interest to note that the locally optimal designs determined in Theorem 2.1 are not
necessarily unique. To see this we consider the case p = 1, where we use the notation f2 = f0
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because the function f2 does not depend on the parameter 2. In this case the model (2.5)
reduces to a linear model
f(d; ) = #0 + #1f0(d); (2.9)
and there also exist locally AC-optimal designs with three or more support points.
Theorem 2.2 Let d1; : : : ; dk 2 XD and ~w1; : : : ; ~wk 2 (0; 1) such that
kX
j=1
~wj = 1 and
kX
j=1
~wjf0(dj) = f0(d
): (2.10)
Then the design with masses ~w1
2
; : : : ; ~wk
2
and 1
2
at the points (d1; 0); : : : ; (dk; 0) and (C; 1) is
a locally AC-optimal design for the model (2.9).
Note that Theorem 2.2 generalizes a result of Herzberg and Cox (1972), who considered
the special case f0(d) = d and showed that designs with masses
1
4
, 1
4
and 1
2
at the points
(d x; 0), (d+x; 0) and (C; 1) are locally AC-optimal designs on the design space X = [L;R]
whenever x  min f d   L;R  d g.
3 Robust optimal AC-optimal designs
Locally optimal designs are often sensitive with respect to misspecication of the initial
parameters and several alternative design strategies have been developed to address this
issue. The literature mainly dierentiates between adaptive/sequential [see Chaudhuri and
Mykland (1995) or Dragalin et al. (2010) among others] and Bayesian/minimax optimal
designs [see for example Chaloner and Verdinelli (1995) and Dette (1997) among others].
In this section we will investigate two robust design strategies for active controlled dose
nding studies, namely minimax and Bayesian AC-optimal designs. To be precise let 
and M denote sets for the possible values for  and , respectively. A design  is called
standardized minimax AC-optimal design for the active control model with respect to the
set  = f = (; )j 2 ;  2 Mg if rd(; ) 2 Range(M(; )) for all (; ) 2  and if
 minimizes the maximum eciency
	M() = maxfe(; ) j  2 g (3.1)
calculated over a given range  of the parameters. The eciency here is dened by
e(; ) =
 (; )
 ( ;
)
2 [1;1]; (3.2)
where  (; ) denotes the criterion function introduced in (2.6) and  is the locally AC-
optimal design. The range  denotes a given set specied by the experimenter which reects
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its prior belief about the unknown vector of parameters. Therefore a design minimizing (3.1)
is expected to yield reasonable eciencies for all values in the set .
Similarly, the Bayesian AC-optimal design minimizes an average of the eciencies. To be
precise let  denote a prior distribution with support given by . Then a design  is called
Bayesian AC-optimal design with respect to the prior  if rd(; ) 2 Range(M(; )) for
all (; ) 2  and if  minimizes a weighted average of the eciencies (3.1), that isZ

e(; )d() (3.3)
From Theorem 2.1 it follows that the eciency in (3.1) and (3.3) is given by
e(; ) =
1
4

1
1  wk+1 g
T (d; ) ~M (~; )g(d; ) +
1
wk+1

where d = d() = f 12 (
 #0
#1
). In general, the determination of standardized minimax and
Bayesian optimal designs is a very dicult problem [see for example Imhof (2001) or Braess
and Dette (2007)] and in most cases these designs have to be found numerically. In the
following discussion we will describe some general properties of these designs and construct
robust optimal designs for some models in explicit form. For this purpose we consider again
model (2.5) and assume that for each parameter  2  the quantity d = f 12 ( #0#1 ) is well
dened and an element of the design space, that is
X0 =
n
f 12
  #0
#1

j  = (#0; #1; T2 ; ) 2 
o
 XD: (3.4)
In other words, for any set of parameters  2  there exists a (unique) dose d = d(; ) 2
XD, such that f(d; ) = . In the following discussion we consider the criterion (3.1) and
(3.3), where the parameter space is of the form
 = f = (#0; #1; T2 ; )T 2  j T2 = g
for some xed vector  2 Rp 1. Throughout this section we assume that  and  contain at
least two points (otherwise we have a locally optimal criterion and the results of the previous
section are applicable). Similarly, if the prior  is supported on the set  we reect this in
our notation, i.e.  = , and assume that  has at least two support points.
3.1 Standardized minimax optimal designs
For a xed 2 =  we introduce for a design of the form (2.4) an induced design on the
design space Z = f f(d) j d 2 XD g by
~ =

z1 : : : zk
~w1 : : : ~wk

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with zi = f(di) 2 Z, i = 1; : : : ; k. It is easy to see that condition (3.4) is equivalent to
Z0 = f f(d) j d 2 X0 g =
n  #0
#1
j  = (#0; #1; 2; )T 2 
o
 Z: (3.5)
Observing that for the model (2.5) we have
d() = f 1

  #0
#1

= f 1 (z
)
with an obvious denition of z = z() = f(d()) it follows that the eciency in (3.2) is
given by
e(; ) =
1
4

1
1  wk+1h(z
; )T ~M (~; )h(z; ) +
1
wk+1

;
where the vector h is dened by
h(z; ) = g(f 1 (z); ) =

1; z;
@f(d; )
@#2

d=f 1 (z)
; : : : ;
@f(d; )
@#p

d=f 1 (z)
T
(3.6)
and ~M(~; ) =
Pk
j=1 ~wjh(zj; )h
T (zj; ). In model (2.5) we have
@f
@#0
= 1; @f
@#1
= f;
@f
@#j
=
#1
@f
@#j
for j  2 and consequently the expression hT (z; ) ~M (~; )h(z; ) does not depend on
the parameters #0; #1 and . Because 2 =  is assumed to be xed, we reect this property
by the notation
hT (z; ) ~M (~; )h(z; ) = hT (z) ~M (~)h(z) (3.7)
where the denition of h(z) and ~M() depend on the specic context. Therefore the opti-
mization problem for the standardized minimax AC-optimal design with respect to the set
 reduces to
min

sup
2
 (; )
 ( ;
)
= min
wk+12(0;1)
min
~
sup
z2Z0
1
4

1
1  wk+1h
T (z) ~M (~)h(z) +
1
wk+1

: (3.8)
As a consequence, the solution of the standardized minimax optimal design can be found in
two steps. First, one determines a minimax optimal interpolation design ~ in a regression
model with Fisher information h(z)hT (z) and design space Z, where the range of interpola-
tion is given by Z0, that is
~ = argmin
~
sup
z2Z0
hT (z) ~M (~)h(z): (3.9)
Secondly, one determines the optimal weight wk+1, which species the proportion of patients
treated with the control. Problems of the type (3.9) have been discussed by Kiefer and
Wolfowitz (1964a,b) for polynomial regression models and these papers indicated that explicit
solutions of (3.9) are extremely dicult to obtain. Additionally, Dette and O'Brien (1999)
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presented further examples. In particular these authors proved the following equivalence
Theorem, which can be used to check the optimality of a given design.
Theorem 3.1 For a design ~ on the induced design space Z dene
d(z; ~) = hT (z)M (~)h(z)
and
(~) =
n
z 2 Z0 j d(z; ~) = sup
x2Z0
d(x; ~)
o
:
Then the following two properties are equivalent:
1. ~ minimizes supz2Z0 d(z; ~).
2. There exists a probability measure  on the set (~), such that for all x 2 Z the
inequality Z
Z0
d2(x; z; ~)d(z)  sup
z2Z0
d(z; ~) (3.10)
holds with d(x; z; ~) = hT (x) ~M (~)h(z). Moreover, in this case there is equality in
(3.10) for each support point of the design ~.
In Subsection 3.3 and 3.4 we will use this result to identify standardized minimax AC-optimal
designs for the model (2.9) and the EMAX model.
3.2 Bayesian optimal designs
An analogue of (3.8) is obtained by similar arguments as in the previous section for the
Bayesian optimality criterion with respect to the prior , that is
	B() =
Z

 (; )
 ( ;
)
d()
=
Z

1
4

1
1  wk+1 g
T (d(); ) ~M (~; )g(d(); ) +
1
wk+1

d()
=
1
4

1
1  wk+1
Z
Z0
hT (z) ~M (~)h(z)dZ0 (z) +
1
wk+1

; (3.11)
where Z0 is the prior induced on the set Z0 by the transformation z = f d. Consequently,
the Bayesian AC-optimal design problem can be solved, by rst determining the design ~
minimizing Z
Z0
hT (z) ~M (~)h(z)dZ0 (z) = tr( ~M
 (~)A) (3.12)
and then determining the optimal weight wk+1, where the matrix A is given by A =R
Z0 h(z)h
T (z)dZ0 (z). Note that the optimality criterion (3.12) is a classical A-optimality
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criterion which has been well studied in the literature. For example, the equivalence theorem
states that a design ~ is A-optimal if and only if the inequality
hT (z) ~M (~)A ~M (~)h(z)  tr( ~M (~)A) (3.13)
holds for all z 2 Z. Moreover, if ~ is A-optimal, there is equality in (3.13) for all support
points of the design ~.
3.3 Linear model
It follows from the denition of model (2.9) that the vector h(z; ) in (3.7) is given by
h(z; ) = (1; z)T . The following results show that standardized minimax and Bayesian AC-
optimal designs for model (2.9) are saturated. The proofs are given in the Appendix.
Theorem 3.2 If assumption (3.4) is satised, then the standardized minimax AC-optimal
design for model (2.9) has at most three support points. Moreover, if XD = [L;R] is an
interval, then the standardized minimax AC-optimal design with respect to the set  is given
by
 =
 
(L; 0) (R; 0) (C; 0)p
(2f0(R) f0(dL) f0(dR))
2(1+
p
)(f0(R) f0(L))
p
(f0(dL)+f0(dR) 2f0(L))
2(1+
p
)(f0(R) f0(L))
1
1+
p

!
(3.14)
where dL = mind2X0 d, dR = maxd2X0 d, and the parameter  is given by
 =
2(2f0(dL)f0(dR)  f0(R)(f0(dL) + f0(dR))  f0(L)(f0(dL) + f0(dR)))
(f0(dL) + f0(dR)  2f0(L))(f0(dL) + f0(dR)  2f0(R)) :
Theorem 3.3 If assumption (3.4) is satised, then the standardized Bayesian AC-optimal
design with respect to the prior distribution  has at most three support points.
Moreover, if XD = [L;R] is an interval, then the standardized Bayesian AC-optimal design
with respect to the prior  on the set  is given by
 =

(L; 0) (R; 0) (C; 1)
p(1  w3) (1  p)(1  w3) w3

where
p =
p
1 + 21 + 2p
1 + 21 + 2 +
p
1  21 + 2 ; (3.15)
w3 =
1
1 + 1
2
(
p
1 + 21 + 2 +
p
1  21 + 2)
and 1 and 2 denote the rst and second moment of the induced prior distribution 
Z0 on
the set Z0, respectively.
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3.4 EMAX model
In our second example we consider standardized minimax and Bayesian AC-optimal designs
for the EMAX model
f(d; ) = #0 +
#1d
1 + #2d
; (3.16)
for which an explicit determination of standardized minimax AC-optimal designs is substan-
tially harder. A straightforward calculation shows that for model (3.16) the gradient of the
regression function can be written in the form
g(d; ) = h(f#2(d); ) = (1; f#2(d); #1f 2#2(d))T ;
where f#2(x) = x=(1 + #2x). Observing the denition of the induced design space Z it
follows that the vector h in (3.6) is given by h(z; ) = (1; z; #1z2)T and (3.7) holds with
h(z) = (1; z; z2)T . The following results describe the standardized minimax and Bayesian
AC-optimal designs with respect to the set .
Theorem 3.4 If assumption (3.4) is satised, then the standardized minimax AC-optimal
design with respect to the set  for the EMAX model (3.16) has at most four support points.
Moreover, if additionally XD = [L;R] and X0 = [dL; dR] are intervals and the set
Z0 =

d
1 + d
j d 2 X0

is symmetric with respect to the center of the interval Z = f([L;R]) the following statements
hold. If
a =
(dR   dL)(1 + L)(1 + R)
(R  L)(1 + dL)(1 + dR)  a0 :=
r
1
6
(5 
p
13) ;
then the standardized minimax AC-optimal design is given by
 =
 
(L; 0) L+R+2LR
2+(L+R)
(R; 0) (C; 1)
p(1  w4) (1  2p)(1  w4) p(1  w4) w4
!
(3.17)
where p = 1
6
(1 + a2) and w4 =

1 +
q
3
2 a2
 1
. Otherwise, if a  a0, the standardized
minimax AC-optimal design is given by (3.17) where
p =
a2(1 + a2)  a(1  a2)p1 + a2
2(3a2   1)
and
w4 =

1 +
q
1  a2 + 2a4 + 2a(1  a2)
p
1 + a2
 1
:
Theorem 3.5 If assumption (3.4) is satised, then the standardized Bayesian AC-optimal
design with respect to the prior distribution  has at most four support points.
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Moreover, if XD = [L;R] is an interval and the induced prior distribution Z0 in (3.11) is
symmetric with respect to the center of the interval Z = f([L;R]), then the standardized
Bayesian AC-optimal design with respect to the prior  is given by
 =
 
(L; 0) L+R+2LR
2+(L+R)
(R; 0) (C; 1)
p(1  w4) (1  2p)(1  w4) p(1  w4) w4
!
; (3.18)
where
p =
p
2 + 4
2(
p
1 + 22 + 4 +
p
2 + 4)
;
w4 =
1
1 +
p
1 + 22 + 4 +
p
2 + 4
;
and j =
R
Z0 z
jdZ0 (z) denotes the jth moment of the induced prior distribution 
Z0
 (j =
2; 4).
4 Examples
In this section we illustrate the methodology by calculating several AC-optimal designs
and investigate the eciency of two designs considered by the clinical team for the active
controlled dose-nding study described in Section 1.
4.1 AC-optimal designs
We determine various AC-optimal designs for the EMAX model (3.16), where the dose range
XD is given by the interval [10; 150]. Information available at the design stage of the dose
nding study led to best guesses of the model parameters, namely #2 = 0:025, #1 = 1:125,
#0 = 2:5 and  = 22:5. By Theorem 2.1 the corresponding locally AC-optimal design is
given by (32; 0) and (C; 1). That is, 50% of the patients are treated with the new drug (at
dose level 32) and the control, respectively. Table 1 displays the locally AC-optimal design
for other parameter constellations, as obtained from Theorem 2.1. For each conguration,
the corresponding locally AC-optimal design advises the experimenter to treat 50% of the
patients with the control and 50% with the new drug at the dose level listed in the table.
#2 #1 #0  local #2 #1 #0  local
0:025 1.145 2.5 22.5 31.0 0:0283 1.145 2.5 22.5 34.5
0:025 1.12 2.5 23.25 34.2 0:0283 1.12 2.5 23.25 38.6
0:025 1.085 2.5 23.5 37.5 0:0283 1.085 2.5 23.5 42.8
Table 1: Locally AC-optimal designs for various parameter specications.
The locally AC-optimal designs considered in Table 1 were calculated under the assumption
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that the elicited parameter values would be the true ones. In order to account for the
uncertainty about the parameter values, we next determine several standardized minimax
and Bayesian AC-optimal designs. We initially keep the parameter #2 = 0:025 xed and
allow some uncertainty for the other parameters. Table 2 displays the results for #0 2 [1; 4]
and dierent example intervals for #1 and . We only show the dose levels and corresponding
weights for the new drug, because the proportion of patients treated with the active control
is easily calculated from these quantities. For example, if
#2 = 0:025; #1 2 [0:91; 1:33];  2 [21:5; 25]; (4.1)
and the standardized minimax optimal design is used, we obtain from the corresponding
row in Table 2 that 12:5%; 32% and 12:5% of the patients should be treated with the new
drug at dose levels 10; 39:2 and 150, while the remaining 43% of the patients are treated
with the standard treatment. The AC-robust designs reported in Table 2 correspond to a
set Z0 which is symmetric with respect to the center of the induced design space Z. The
Bayesian AC-optimal designs have been calculated with respect to the uniform distribution
on X0 and were determined numerically, even when assuming a xed parameter #2 = 0:025,
because the induced prior distribution is not symmetric. The corresponding standardized
minimax AC-optimal designs in Table 2, however, were calculated using Theorem 3.4. For
example, in the scenario (4.1) the set X0 dened in (3.4) is given by X0 = [19:61; 77:83]
which yields L = 10; R = 150 and dL = 19:61; dR = 77:83. The induced design space is given
by Z = [8; 31:58] and we obtain Z0 = f#2(X0) = [13:16; 26:42]. Therefore, the standardized
AC-optimal design can be directly obtained by an application of Theorem 3.4.
In order to obtain ecient designs which are robust against misspecication of #2, Table 2
also displays the results under the assumption that an interval for the parameter #2 is
specied, more specically that #2 2 [0:023; 0:027] and #2 2 [0:016; ; 0:025]. In this case,
the standardized minimax AC-optimal designs have to be determined numerically as well.
A comparison of the standardized minimax optimal designs shows only minor dierences
between the cases #2 2 [0:023; 0:027] and #2 = 0:025. However, if #2 2 [0:016; 0:025] the
smallest dose level 10 receives more weight while the highest dose level 150 received less
weight. Moreover, the dose level in the interior design space XD is larger. It is interesting to
note that the proportion of patients treated with the active control is essentially not changing
if there is more uncertainty about the parameter #2. Similar observations can also be made
for the Bayesian AC-optimal designs.
If the set Z0 is not symmetric all designs have to be calculated numerically, even in the case
where the parameter #2 is xed. Table 3 displays results for some examples in this case.
There are no major dierences between the Bayesian AC-optimal designs for #2 = 0:025 and
#2 2 [0:023; 0:027]. The dierences between the standardized minimax AC-optimal designs
are more pronounced. The lowest dose level receives approximately three times more weight
if uncertainty about the parameter #2 is taken into account in the optimality criterion. In
addition, the weight at the dose level in the interior design space is decreased by 25%.
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#2 #1  Bayes minimax
10 35.2 150 10 39.2 150
[0:86; 1:43] [19; 26]
0.09 0.41 0.05 0.16 0.28 0.16
10 36.5 150 10 39.2 150f0:025g [0:91; 1:33] [21:5; 25]
0.06 0.44 0.04 0.125 0.32 0.125
10 38.0 150 10 39.2 150
[0:97; 1:20] [23; 24]
0.03 0.47 0.03 0.08 0.39 0.08
10 35.2 150 10 37.1 150
[0:86; 1:43] [19; 26]
0.09 0.41 0.06 0.15 0.26 0.19
10 36.6 150 10 39.7 150[0:023; 0:027] [0:91; 1:33] [21:5; 25]
0.06 0.44 0.04 0.14 0.32 0.11
10 38.1 150 10 39.2 150
[0:97; 1:20] [23; 24]
0.03 0.47 0.03 0.08 0.38 0.10
10 33.9 150 10 42.9 150
[0:86; 1:43] [19; 26]
0.11 0.40 0.04 0.19 0.27 0.14
10 34.1 150 10 43.1 150[0:016; 0:025] [0:91; 1:33] [21:5; 25]
0.08 0.43 0.03 0.17 0.32 0.09
10 34.6 150 10 41.1 150
[0:97; 1:20] [23; 24]
0.05 0.46 0.02 0.13 0.37 0.07
Table 2: Bayesian and standardized minimax AC-optimal designs for various specications
for the parameter #1, #2 and  where the intercept satises #0 2 [1; 4]. The set Z0 dened in
(3.5) is symmetric with respect to the center of the induced space Z. First row: dose levels
of the new compound. Second row: proportion of patients treated at these dose levels.
Again the proportion of patients treated with the control is essentially the same in all three
scenarios, regardless of whether a Bayesian or standardized minimax approach is employed.
Note that the intermediate dose level for the Bayesain AC-optimal is smaller than for the
standardized minimax AC-optimal design. Moreover, the weights at the dose levels 10 and
150 are mostly smaller for the Bayesian designs compared with the minimax designs.
4.2 Relative eciencies
In this section we investigate the relative eciencies of the robust designs determined in
Section 4.1 in comparison with two designs considered by the clinical team at the planning
stage of the dose nding study. These two standard designs S1 and S2 reect the current
practice of allocating patients equally across several doses, which are often chosen to be
equally distant in the original or in a logarithmic scale, that is
S1 =

(10; 0) (45; 0) (80; 0) (115; 0) (150; 0) (C; 1)
1
6
1
6
1
6
1
6
1
6
1
6

; (4.2)
S2 =

(10; 0) (20; 0) (39; 0) (76; 0) (150; 0) (C; 1)
1
6
1
6
1
6
1
6
1
6
1
6

: (4.3)
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#2 Bayes minimax
10 34.0 150 10 39.2 150f0:025g B1 0.07 0.44 0.03 M1 0.05 0.44 0.05
10 33.9 150 10 39.9 150
[0:023; 0:027] B2 0.07 0.44 0.03
M2 0.14 0.33 0.10
10 31.9 150 10 43.4 150
[0:016; ; 0:025] B3 0.09 0.42 0.02
M3 0.18 0.34 0.05
Table 3: Bayesian and standardized minimax AC-optimal designs under the assumption that
#0 2 [1; 2], #1 2 [0:92; 1:38] and  2 [20; 23]. The range for the parameter #2 is shown in
the rst column. The induced space Z0 dened in (3.5) is not symmetric with respect to the
center of the induced design space Z. First row: dose levels of the new compound. Second
row: proportion of patients treated at these dose levels.
It follows from the discussion in Section 3 that the relative eciencies depend on the unknown
parameter  only through the target dose d = f 1#2 (
 #0
#1
). Table 4 exemplarily displays the
relative eciencies of various designs for estimating the target dose d = 32. A design is
better if its relative eciency (which is always larger or equal than 1) is closer to 1. As
seen from Table 4 the robust designs achieve considerably better relative eciencies than
the two standard designs. The Bayesian AC-optimal designs usually yield better relative
eciencies for estimating the target dose than the minimax AC-optimal designs. However,
this observation depends on the specic target dose (in our case d = 32). This can be seen
in Figure 1, where we exemplarily show the relative eciency of the standardized minimax
AC-optimal design M3 and Bayesian AC-optimal design B3 for various values of the target
dose d and the parameter #2 (these are determined by the specication of the set ). We
observe that the relative eciencies of the standardized minimax AC-optimal designs vary
between 1:6 and 2:0, while the range of eciencies obtained from the Bayesian AC-optimal
design is considerably larger, namely [1:4; 3:9]. If, for example, the target does is d = 45,
the standardized minimax AC-optimal design performs better than the Bayesian AC-optimal
design.
Finally, we compare these surface with the corresponding relative eciencies obtained from
the two standard designs, as displayed in Figure 2. Both standard designs perform uniformly
worse than the standardized minimax AC-optimal design. The eciency of the equidistant
design S1 varies between 2:5 and 2:9, while the eciency of the design S2 is smaller and
varies between 2:1 and 2:5. On the other hand the Bayesian AC-optimal design outperforms
the two standard designs whenever the target does is less than 45 and larger than 20. If
S1 S2 B1 B2 B3 M1 M2 M3
e(; ) 2.94 2.40 1.58 1.58 1.66 1.68 1.89 1.95
Table 4: Relative eciencies of reference and robust designs for estimating the target dose
d = 32.
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Figure 1: Relative eciencies of the designs B3 and M3 with varying parameter #2 2
[0:016; ; 0:025] and target dose d 2 [16:7; 59:5].
Figure 2: Relative eciencies of the references designs S1 and S2 with varying parameter
#2 2 [0:016; ; 0:025] and target dose d 2 [16:7; 59:5].
d < 20 there are no substantial dierences between the Bayesian AC-optimal and the two
standard designs, while the latter have a better performance if d > 45. On the basis of these
calculations (and similar results for other parameter specications, which are omitted here
for the sake of brevity), we recommend using a standardized minimax AC-optimal design.
5 Conclusion
In this paper we present a rigorous approach for the construction of optimal designs for dose
nding studies with an active control. Despite of their practical importance, optimal design
problems of this type have not been studied in the literature so far to our best knowledge.
Locally optimal designs for estimating the target dose are derived explicitly. These designs
are used for the construction of robust designs which require much less prior knowledge
about the parameters of the model used for describing the dose response relationship. It is
demonstrated that the new designs outperform several standard designs which are currently
used in clinical practice.
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A challenging future research project in this context is the important problem of model
uncertainty which typically appears in this type of investigations, because in many appli-
cations it is very dicult to specify an adequate nonlinear model for the description of the
dose response relationship. In most cases there exist several competing models (e.g. EMAX,
log-linear and logistic) for this purpose. A typical strategy to obtain a good model for the
description of the dose response relationship is to test the null hypothesis of a constant
dose-response curve at a signicance level of, say 5% (adjusted for multiplicity), against the
alternative hypothesis of a non-constant dose response curve for each of the four candidate
models. Among those models where the null hypothesis is rejected, the model with the
highest value of the AIC (Akaike information criterion) will be selected for the estimation of
the target dose, see e.g. Bretz et al. (2005). In a recent paper Dette et al. (2008) proposed
model robust designs for MED estimation for a class of \classical" dose nding models by
maximizing multiple objective criteria [see for example Cook and Wong (1994)]. In the fu-
ture we plan to adapt this methodology to the problem of constructing AC-optimal designs
for several competing active control models [see also Bornkamp et al. (2011) for a Bayesian
approach to address model uncertainty in a \classical" dose nding study].
In this paper we focused on one possibility of estimating a target dose that takes the treat-
ment eect of an active control into account. However, alternative target dose denitions
might be used in special situations. For example, if the safety prole of the new compound is
better than that of the active control, one might be interested in estimating the smallest dose
that is not relevantly inferior, i.e. d = d(; ; ) = f 1(; ; ) = f 12 (
  #0
#1
) for a xed
non-inferiority margin  > 0. Yet a dierent alternative target dose arises in dose nding
studies which include both an active control and placebo. In such situations, one might be
interested in a combined objective by estimating the smallest dose that is not worse than
the active control and is still better than placebo by a certain clinically relevant amount.
A careful inspection of the proofs in Section 6 shows that the methodology can directly be
applied to this problem by replacing  with   ; details are left to the reader.
A dierent line of research is to derive optimal designs for endpoints that do not follow a
normal distribution. For example, in chronic gout studies (which is a dierent situation than
the acute gout study considered in Section 1) the primary endpoint is often dened as the
number of ares occurring per subject within 16 weeks of randomization. These ares can
be modeled using a negative binomial distribution and a common overdispersion (variance
divided by expectation minus 1) for all treatment arms. The logarithm of the expectation
of the number of ares during 16 weeks is then described by a regression model for the dose-
response relationship between the (single) dose groups of the new compound and a constant
parameter for the comparator. Again, we leave the determination of optimal designs in such
situations for future research.
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6 Appendix. Technical details
Proof of Theorem 2.1: We will show at the end of this proof that for the models under
consideration we have
@d(; )
@
g(d; ) =  rd(; ); (6.1)
where r denotes the gradient with respect to the parameter . Therefore we obtain for the
gradient with respect to  = (; )
rd(; ) =

rT d(; );
@d(; )
@
T
=
@d(; )
@
  gT (d; ); 1T ;
and the optimality criterion dened in (2.6) is in fact a special case of the c-optimality
criterion (2.7) with the vector
c = ( gT (d; ); 1)T : (6.2)
It can be shown [see Pukelsheim (2006)] that a design  minimizes cTM (; )c if and only
if there exists a generalized inverse G of M (; ) such that for all (d; ) 2 X the inequality
cTM (; )c   T ((d; ); )Gc2 (6.3)
is satised. Moreover, equality holds in (6.3) for all support points of any locally c-optimal
design. Therefore a design  is a locally optimal AC-design if and only if there exists a
generalized inverse of the matrix M( ; ), such that the inequalities
cTM ( ; )c 
 
(gT (d; ); 0)Gc
2
(6.4)
cTM ( ; )c  ((0; 1)Gc)2 (6.5)
hold for all d 2 XD, where the vector c is given by (6.2). Note that the inequalities (6.4) and
(6.5) correspond to the case  = 0 and  = 1 in (2.7), respectively. The information matrix
of the candidate design  dened in (2.8) is obtained as
M( ; ) =
1
2

g(d; )gT (d; ) 0
0 1

:
Observing that in model (2.5) the rst coordinate of the vector g(d; ) is given by 1 it
now follows by a straightforward calculation that the matrix G = 2
 
e1e
T
1 + ep+2e
T
p+2

is
a generalized inverse of the information matrix M( ; ), where ei 2 Rp+2 denotes the i-
th unit vector. Using this generalized inverse in the equivalence theorem with the vector
c = ( g(d; )T ; 1)T it follows that the design  fullls the inequalities (6.4) and (6.5)
because both sides are equal to 4.
We conclude the proof showing the relation (6.1) which is essential for the argument above.
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For this purpose we recall the denition of the vector  = (; )T 2 Rp+2 and consider the
function
F (; d) =   f(d; ):
By assumption there exists a solution, say d() = d(; ) of the equation F (; d) = 0
with respect to d and @f(d;)
@d
6= 0. Therefore the implicit function theorem implies that the
function  ! d() is dierentiable with derivative
@d()
@
=  

@F (; d)
@d

d=d()
 1
@F (; d)
@

d=d()
=  

@F (; d)
@d

d=d()
 1
( gT (d; ); 1)T :
This yields
rd() =

@F (; d)
@d

d=d()
 1
g(d; );
@d()
@
=  

@F (; d)
@d

d=d()
 1
;
and proves (6.1), which completes the proof of Theorem 2.1. 
Proof of Theorem 2.2: In model (2.9) the gradient in (2.2) is given by g(d; ) = (1; f0(d))
T
and we obtain from (2.10) and Elfving's theorem [see Elfving (1952)] that the design ~
dened in (2.4) minimizes gT (d; ) ~M (~; )g(d; ) where the minimum value is given by 1.
Therefore it follows from Theorem 2.1 that the design  dened in Theorem 2.2 is locally
AC-optimal. 
Proof of Theorem 3.2: We rst show that the optimal design ~ dened by (3.9) is
supported at at most 2 points, which implies the statement regarding the number of support
points. For this purpose we apply Theorem 3.1 and recall that for model (2.9) the vector h
in this criterion is given by h(z; ) = (1; z)T . Consequently, it is easy to see that the left
hand side of inequality (3.10) is a polynomial of degree 2. Because equality holds in (3.10)
for all support points of ~ this implies that the optimal design ~ has at most 2 support
points. Consequently, the standardized minimax AC-optimal design has at most 3 support
points.
We will also use Theorem 3.1 to show that the design ~ minimizing (3.9) is of the form
~ =
 
zL zR
zl+zr 2zR
2(zL zR) 1 
zl+zr 2zR
2(zL zR)
!
(6.6)
where the points zL, zR, zl and zr are dened by zL = f0(L) = mind2XD f0(d), zR = f0(R) =
maxd2XD f0(d), zl = f0(dL) = mind2X0 f0(d) and zr = f0(dR) = maxd2X0 f0(d), respectively.
For this purpose we note that a straightforward but tedious calculation gives (~) = fzl; zrg
in Theorem 3.1. Equivalently, hT (zl) ~M
 1(~)h(zl) = hT (zr) ~M 1(~)h(zr), where h(z) =
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(1; z)T and ~M(~) =
R
h(z)hT (z)d~(z): This yields
sup
z2Z0
d(z; ~) = d(zl; ~) = 1  (zl   zr)
2
(zl + zr   2zL)(zl + zr   2zR)
and
d2(x; z; ~) =
4(x(2z   zl   zr)  z(zl + zr) + zL(zl + zr) + (zl + zr   2zL)zR)2
( 2zL + zl + zr)2( 2zR + zl + zr)2 :
If  is a prior distribution on the set (~) with weights p and 1  p at the points zl and zr,
respectively, we haveZ
z2Z0
d2(x; z; ~)d(z) = pd2(x; zl; ~) + (1  p)d2(x; zr; ~) = P2(x):
If the design ~ in (6.6) was optimal, then it follows from Theorem 3.1 that for x = zL there
must be equality in (3.10) which determines the weight p, that is
p =
1
2

2 +
zL   zl
zr + zl   2zL +
zR   zl
zr + zl   2zR

:
The function P2(x) is a polynomial of degree two, with positive leading coecient
4(zl   zr)2
( 2zL + zl + zr)2( 2zR + zl + zr)2
and minimum at the point zL+zR
2
. Therefore it attains maxima in the set Z at the points
zL and zR with value d(zl; ~
) and by Theorem 3.1 the design ~ is optimal i.e. it minimizes
(3.9). For the determination of the standardized minimax AC-optimal design it remains to
determine the weight w3. Inserting ~
 into (3.8) leads to
k(w3) =
1
1  w3h(z
) ~M 1(~)h(z) +
1
w3
=

1  w3 +
1
w3
;
where
 =
2(2zlzr   zR(zl + zr)  zL(zl + zr   2zR))
(zl + zr   2zL)(zl + zr   2zR) :
The function k is minimal for w3 =
1
1+
p

and with denition (2.4) it follows that
w1 =
p
(2zR   zl   zr)
2(1 +
p
)(zR   zL) and w2 =
p
(zl + zr   2zL)
2(1 +
p
)(zR   zL) :
Resubstitution of zl; zr; zL and zR shows that the design given by (3.14) is standardized
minimax AC-optimal. 
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Proof of Theorem 3.3: It follows from the discussion in Section 3.2 that the Bayesian
AC-optimal design can be found by solving the A-optimal design problem (3.12), where
A = (i+j)i;j=0;1 = (
R
Z0 z
i+jdZ0 (z))i;j=0;1 and h(z) = (1; z)
T . The statement regarding the
support points is obtained in the same way as given in the proof of Theorem 3.2 using the
inequality (3.13). A further application of (3.13) shows that the design ~ with masses p
and 1   p at the points  1 and 1 minimizes (3.12), where the weight p is given by (3.15).
The corresponding minimal value is given by
tr(M 1(~)A) =
1
4
p
1  21 + 2 +
p
1 + 21 + 2
2
Therefore the assertion follows by minimizing the expression (3.11) with respect to the
remaining weight w3 and transforming the design ~
 onto the design space XD. 
Proof of Theorem 3.4: The statement regarding the number of support points follows
along the lines given in the proof of Theorem 3.2, where in this case the vector h in (3.7)
is given by h(z) = (1; z; z2). In order to prove the second part of the result we note that
the set Z0 is an interval and consequently the design  minimizing (3.9) has a nonsingular
information matrix M(~) and has therefore exactly 3 support points. Note also that the
criterion d(z; ~) = hT (z)M 1(~)h(z) is invariant with respect to linear transformations of
the form z ! z+ of the set Z0 and Z and therefore we assume without loss of generality
that Z = [ 1; 1] and Z0 = [ a; a]. From a standard convexity argument it follows that the
design ~ minimizing
max
z2[ a;a]
hT (z) ~M 1(~)h(z)
is symmetric with masses p; 1  2p; p at the points  1; 0; 1 and inverse information matrix
~M 1(~) =
1
2p(1  2p)
0@ 2p 0  2p0 1  2p 0
 2p 0 1
1A :
Recalling the denition of the optimization problem (3.8) we obtain that the function z !
hT (z) ~M 1(~)h(z) is a symmetric polynomial of degree 4 with positive leading coecient.
Therefore the maximum in (3.9) is attained at most at the two boundary points of the set Z0
and one interior point of Z0, and it follows by symmetry that we have to distinguish three
cases for the set (~) in Theorem 3.1, that is
(1) (~) = f a; 0; ag; (2) (~) = f a; ag; (3) (~) = f0g:
In the rst case we note that the identity d(a; ~) = d(0; ) determines the weight p, i.e.
p = 1
6
(1 + a2) with value
max
z2[ a;a]
d(z; ~) = d(0; ) =
3
2  a2 : (6.7)
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In the second case the condition
d( a; ~) = d(a; ~) = 2p+ (1  6p)a
2 + a4
2p(1  2p) (6.8)
is satised for any symmetric design and cannot be used to determine p directly. However,
the optimal design would minimize maxz2[ a;a] d(z; ~) = d(a; ~), and this yields
p =
a2 + a4  pa2(1  a2)(1  a4)
2( 1 + 3a2) (6.9)
with value
max
z2[ a;a]
d(z; ~) = d(a; ~) = 1  a2 + 2a4 + 2a(1  a2)
p
1 + a2: (6.10)
Finally, for the third case note that by (6.8) the inequality (1  2p) 1 = d(0; ~) > d(a; ~)
is equivalent to the inequality p  (1 + a2)=6. Therefore minimizing (1  2p) 1 with respect
to this condition gives p = (1+ a2)=6 and a design satisfying (1), that is (~) = f a; 0; ag.
Consequently, the third case can not occur and we only have to compare the results corre-
sponding to cases (1) and (2), for which the optimal values are given by (6.7) and (6.10),
respectively. A simple calculation shows that the inequality
3
2  a2  1  2a
2 + 2a4 + 2a(1  a2)
p
1 + a2
holds in the interval [0; 1] if and only if the inequality a  a0 =
q
(5 p13)=6  0:482087
is satised. It follows that the criterion (3.9) is minimized for the design ~ with masses
p; 1   2p; p at the points  1; 0; 1, respectively, where the weight p is given by (1 + a2)=6 if
a  a0 and (6.9) if a < a0. The assertion of Theorem 3.4 nally follows by transforming
these results to the original design space (note that the transformation is nonlinear). 
Proof of Theorem 3.5: We may assume without loss of generality that Z = [ 1; 1].
Now by assumption the induced prior distribution is symmetric and as a consequence the
elements in the matrix A = (
R
Z0 z
i+jdZ0 (z))
2
i;j=0 vanish, whenever i + j is odd. Therefore
a standard argument shows that there exists a symmetric design ~ minimizing (3.12) and
in the following we will investigate if a symmetric design supported at the points  1, 0, and
1 is optimal. For such a design the optimal weights can be computed using a result from
chapter 8 in Pukelsheim (2006), which gives for the corresponding weights
~w1 = ~w3 =
p
2 + 4
2(
p
1 + 22 + 4 +
p
2 + 4)
; ~w2 =
p
1 + 22 + 4p
1 + 22 + 4 +
p
2 + 4
;
respectively, where j denotes the jth moment of the distribution 
Z0
 . Finally, a straightfor-
ward application of the equivalence theorem (3.13) shows that the design with weights ~w1; ~w2
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and ~w3 at the points  1; 0 and 1 is in fact minimizing (3.12). The value of the corresponding
criterion in (3.12) is given by
 p
1 + 22 + 4 +
p
2 + 4
2
. Minimizing the criterion (3.11)
with respect to the remaining weight w4 and transforming the support points from the in-
duced design space Z to the given design space XD shows that the Bayesian AC-optimal
design with respect to the prior  is given by (3.18), which completes the proof of Theorem
3.5. 
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